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Anaphylaxis Mediated Through a  Humanized High Affinity 
IgE Receptor’ 
David Dombrowicz,* Anna T. Brini,’ Wronique Flamand,*  Elizabeth Hicks,* 
John N. Snouwaert,*  Jean-Pierre  Kinet,§  and  Beverly H. Koller2’ 
Mast  cells  and  basophils, which are activated by Igf and  allergens  through the high  affinity IgE receptor (FctRI), play  a  prom- 
inent role in anaphylaxis in the mouse. Mice deficient in this  receptor  become  resistant to passive  anaphylaxis. As a  first step 
in developing an in vivo model that more closely mimics the IgE-mediated responses in man, we used a combination of 
transgenic  and  embryonic  stem cell technology to generate  a mouse line in which the murine FceRl a-chain has been  replaced 
with its human  homologue. We demonstrate here that these mice express a tetrameric high  affinity IgE receptor, in which  the 
human a-chain associates with the murine p- and  y-chains,  and that upon  triggering with relevant Ag, this receptor  mediates 
the initiation of the expected intracellular events. In addition, we show that the human a-chain restores an anaphylactic 
response to the nonresponsive a-deficient parental mouse line. This “humanized” mouse represents a potentially important 
model system, not only for studying the role of IgE in human immune responses, but also for testing potential therapeutic 
reagents that can interfere with responses mediated through the human FceRI receptor. The Journal of immunology, 1996, 
157: 1645-1651. 
A ttempts to understand the workings of the human im- mune system have led to the development of a wide variety of experimental systems. These include systems 
in which the interactions of isolated components of the  immune 
system can be studied in  vitro  as well as animal models that allow 
immune responses to be studied in the complex environment 
where they normally occur. Of the animal models that have been 
developed for  the study of immune responses in vivo, the mouse is  
the species that has been the most widely used. However, despite 
the fact that studies using mice have provided valuable insights 
into the workings of the human immune system, the application of 
information generated by such  studies to the treatment of human 
disease  has  often been limited by the fact that murine and human 
immune responses differ from one another in many important 
ways. To increase the usefulness of the mouse as a model system 
for understanding human immune responses, it would therefore be 
desirable to create mice in which the immune system more ciosely 
resembles  that of humans. This has been accomplished at the cel- 
lular Level by introducing human hemopoietic stem cells into  mice 
such  as  the severe combined immunodeficiency mouse, which car- 
ries a mutation that impairs the development of the endogenous 
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hemopoietic system (1). Another approach would alter mice at the 
genetic level, replacing genes that encode important immune func- 
tions with their human homologues (2). To develop better models 
for the study of anaphylaxis and allergic responses jn vivo, we 
have used this second approach to create mice in which the en- 
dogenous gene encoding the a-subunit of the high affinity IgE 
receptor, FcERI,~ has been inactivated and replaced with its human 
homologue. 
FccRI belongs to the Fc receptor superfamily ( 3 ,  4). It has a 
tetrameric structure composed of one a-, one j3-, and two y-sub- 
units. The  a-subunit directly binds IgE (5). while the 0- and y-sub- 
units appear to function primarily in signal transduction (6). FcaRI 
receptors on mast cells and basophils undergo aggregation upon 
binding IgE and multivalent Ags, leading to the release of medi- 
ators of allergic reactions. Mast cells in both humans and mice 
express receptors in addition to the high affinity IgE receptor that 
bind IgG and IgE (7, 8). In humans, FccRI is also present on 
Langerhans cells (9, IO), on monocytes from atopic individuals 
(1 I), and on eosinophils in some pathologic states (12). Transfec- 
tion experiments have shown that the presence of the  P-subunit is 
necessary for surface expression of rodent receptors, while the 
y-subunit alone has been found to  be sufficient to allow surface 
expression of the human  a-subunit (13). 
The centra1 role of FcERT in mediating anaphylaxis was estab- 
lished by the demonstration that mice deficient in this receptor fail 
to undergo passive anaphylaxis (14). These mice were generated 
by homologous recombination in ES cells using a plasmid de- 
signed to disrupt the mouse LY chain, Here we report the reconsti- 
tution of the anaphylactic response in these mice through the in- 
troduction into their germ line of a transgene encoding the human 
(h) FcaRI a-chain. 
onic stem; h, human; m, mouse; HPRT, hypoxanthine phosphate ribosyltrans- 
’ Abbreviations used in this paper: FcaRI, high affinity IgE receptor; ES, embry- 
ferase;  BMMC, hone marrow-derived mast  cells;  NIP, 4-hydroxy-3-nitrophenyl- 
acetyl; PVDF, polyvinylidene difluoride; HSA, human serum albumin. 
Copyright 0 1996 by The American Association of Immunologists 0022-1 767/96/$02.00 
1646 ANAPHYLAXIS  MEDIATED THROUGH HUMANIZED IgE  RECEPTOR 
Materials and Methods 
Isolation and characterization of the human a gene 
A  9.5-kb  BamHi fragment containing the hFceRIa gene was isolated from 
a human leukocyte genomic library generated with the EMBL3 h phage 
vector (Clontech,  Palo  Alto,  CA) using the full-length hFcsRIa cDNA as 
a probe (15). 
Transgenic animals 
Five micrograms of the 9.5-kb fragment containing the hFceRIa gene and 
5 pg of the plasmid HPRTSO (16), a plasmid containing the hprf minigene, 
were introduced by calcium phosphate precipitation into the ES cell line 
ES65-154 (14) essentially as described previously (17). 
ES cell colonies were visualized 10 days later after selection in hypo- 
xanthine-aminopterin-thymidine-medium, and individual colonies were 
picked and expanded. DNA was prepared from 12 of these colonies. Anal- 
ysis by Southern blot, using the full-length hFceRIa cDNA as a probe, 
showed that nine of these had integrated the transgene. ES cells  from  two 
unique clones were introduced into 3.5-day-old C57BU6 blastocysts and 
implanted into foster mothers. Chimeras were generated from both of these 
lines. Female chimeras were used for  the analysis described below. Male 
chimeras, which are in general more likely to transmit the ES cell genome 
than their female siblings, were bred to female  FceRIa -/- mice to obtain 
mice that were homozygous for the mutant murine FceRIa gene and that 
also  carried the transgene encoding  hFceRIa. 
Bone marrow-derived mast cells (BMMC) 
BMMC were obtained as previously described ( 1  8). Briefly, bone marrow 
was aseptically obtained from 6-wk-old animals and placed in culture for 
3 wk in the presence of IL-3-conditioned medium. Nonadherent cells were 
transferred weekly into fresh medium. 
Antibodies  and FACS staining 
Murine anti-DNP  IgE (clone SPE-7) was obtained from Sigma Chemical 
Co. (St. Louis, MO). TANE, a chimeric IgE molecule (hIgE-Fc, mouse 
anti-NIP IgE-Fab) was obtained from Serotec  (19).  TANE will be referred 
to as hIgE throughout this article. 
The 15-1 anti-hFceRIa  mAb has been described previously (10). FACS 
staining was performed for 30 to 60 min at 4°C in 100 p1 of PBS con- 
taining 0.1 % BSA and 0.05% sodium azide at 5 X to6 cells/ml. All murine 
cells were preincubated before staining with hybridoma supernatant from 
2.4G2 Ab-producing cells (20) to block IgE binding to FcyRIIIRIII. Con- 
centrations used for staining were 10 pglml  for hIgE-biotin and 112500 for 
streptavidin-phycoerythrin (PharMingen, San Diego, CA). The specificity 
of binding to hFceRIa was checked by preincubation with 150 p.g/ml 
unlabeled 15-1. To quantify the expression of the mouse receptor on 
BMMCs, cells were preincubated with 15-1 and then stained with DNP- 
specific biotinylated mouse IgE and 1/2500 diluted streptavidin-phyco- 
erythrin. Samples were analyzed on a FACScan cytofluorimeter (Becton 
Dickinson, Mountain View,  CA). 
Western blot 
BMMCs (1.5 X lo’) from wild-type and transgenic animals were loaded at 
4°C for 3 h with 10 &ml 15-1 at 5 X lo6 cells/ml and then washed three 
times with PBS.  Cells were lysed at 5 X 107cells/ml in 1% digitonin, 150 
mM NaCl, 50 mM HEPES (pH 7.4), 10 pg/ml aprotinin, I O  pg/ml pep- 
statin, 5 pg/ml leupeptin (ICN Biochemicals, Costa  Mesa,  CA) on ice for 
30  min.  The lysate was then centrifuged for 20 min at 4°C. The supernatant 
was removed and immunoprecipitated for  2  h at 4°C with 40 pl of Gam- 
maBind Plus Sepharose beads (Pharmacia, Piscataway, NJ) and then for  an 
additional 2  h with 40  pl  of beads coated with 10 p g  of 15-1. Samples were 
loaded on 14% SDS-polyacrylamide Tris-glycine gel (Novex Experimental 
Technologies). After electrotransfer, PVDF membrane (Millipore Corp., 
Bedford, MA) was probed with a  mAb against rat FceRIP (JRK) (21) and 
anti-murine FceRly antiserum (22). Revelation was performed using anti- 
mouse and anti-rabbit horseradish peroxidase-conjugated Abs (Amersham 
Corp.. Arlington Heights, IL)  and the ECL kit (Amersham) according to 
the manufacturer’s instructions. Lysates from BMMCs, thymocytes, and 
splenocytes were immunoprecipitated with the 15-1 Ab, and the immuno- 
precipitate was fractionated under nonreducing conditions on 8% acryl- 
amide gels, electrotransferred to a PVDF membrane, and probed with a 
polyclonal Ab specific for the hFceRI a-chain. Revelation was performed 
using anti-mouse and anti-rabbit HRP-conjugated Abs (Amersham) and the 
ECL kit (Amersham) according to the manufacturer’s instructions. 
Calcium flux measurement 
BMMC from either transgenic or wild-type animals were loaded at 5 X IOh 
cells/ml for 45 min at 25°C with the acetoxymethylester of fura-2 (Mo- 
lecular Probes, Eugene, OR;  2 pM) in a buffer, pH 7.4, containing 135 mM 
NaCI, 5 mM KCI, 1 mM CaCI,,I mM MgCI,, 5.6 mM glucose, 10 mM 
HEPES, 0.1 % BSA, and 2.5 mM Probenecid. Cytoplasmic free  Ca2+ was 
measured on a Photon Technology International Deltascan 4000 spec- 
trofluorimeter at 500 nm with a cell suspension alternatively excited at 340 
and 380 nm. Cells were loaded first with 5 pg/ml hIgE and triggered with 
100 ng/ml NIP-BSA, then with 5 pgfml mIgE and triggered with 100 ng/ml 
DNP-HSA. Calcium concentrations were calculated using the published 
value of 2.24 X 10”  for the Kd for fura-2 at 37°C (23). 
Serotonin release assay 
A serotonin release assay was performed according to  Takizawa  et al. (8). 
BMMC from chimeric mice as well as from wild-type animals were loaded 
overnight with 1 pCi/ml 5-[I ,2-N-3H]hydroxytryptamine binoxalate 
([‘Hlserotonin) at 1 X IO6 cells/ml in complete RPMI. For triggering 
through the human receptor, cells were loaded with 5 pg/ml  hIgE (anti- 
NIP) at 37°C for  2  h  at  2.5 X lo6 cells/ml in medium. For selective trig- 
gering through the murine receptor, cells were first loaded with 75 pg/ml 
nonspecific higE (obtained from human serum) for 1 h then with 5 pg/ml 
murine anti-DNP  IgE  for  2 additional h.  The cells were washed three times 
with medium  and incubated at  2.5 X lo6 celldm1 with various concentra- 
tions of specific Ag (NIP-BSA for  hIgE  and DNP-HSA for  mlgE). Dupli- 
cate samples were analyzed for each Ag concentration. 
Passive systemic anaphylaxis 
Passive systemic anaphylaxis was performed as previously described (14). 
Briefly, animals were injected i.v. with 200 pl  of PBS containing 20 pg  of 
a monoclonal mouse anti-mouse DNP  IgE and 24 h later with 200 pI of 
PBS containing 1% Evans blue dye  and  1 mg of DNP-HSA. Control an- 
imals received only Ag. Baseline temperature was established for each 
animal using a rectal probe before injection of the Ag. Temperature drops 
due to anaphylactic response were recorded 30 min after the injection of 
Ag. Animals were then killed, and edema was quantitated. Seven-milli- 
meter ear punches were obtained from each ear, and the Evans blue dye 
was extracted by incubation in 1 ml  of formamide at  55°C for 48  h  and was 
quantitated by measuring the absorbance of fomamide at  610 nm with a 
spectrophotometer (24). Significance of results was determined using a 
two-sample f test. 
Results 
Generation of mice expressing hFceRla 
The initial transgene construct with which we attempted to obtain 
expression of hFceRIa in mice was based on the plasmid pCDL- 
SRa (25). The transgene in this construct consisted of a hFceRIa 
cDNA driven by a  SV-HTLV promoter with a  SV40  poly(A)  sig- 
nal. To allow for selection of stable integrants after electroporation 
into mouse ES cells,  this construct was modified by the addition of 
a neomycin resistance gene downstream of the FceRIa transgene 
to yield a plasmid designated pHuaNeo. Although the pCDL-SRa 
construct had been demonstrated previously to yield expression of 
hFceRIa after transfection into RBL, Chinese hamster ovary, and 
NIH3T3 cells, the pHuaNeo did not yield detectable expression of 
the hFceRIa transgene in mice after integration into the murine 
genome. One possible reason for this apparent lack of expression 
was the absence in the cDNA-based construct of uncharacterized 
cis-activating elements in the 5’ noncoding region or introns of the 
endogenous FceRIa gene. To circumvent this problem, we created 
a new construct using genomic rather than cDNA sequences. We 
isolated a 9.5-kb BarnHI fragment from a human genomic library, 
using a full-length human cDNA as a probe (Fig. 1) .  This clone 
encompasses the entire coding sequence of the  gene as well as 2.9 
kb  of upstream sequence, which extends 1.6 kb upstream from the 
previously published sequence (26). 
The hFceRIa gene was introduced by  Ca,PO, precipitation into 
the mouse ES cell line, E14TG2a-165. To allow for enrichment of 
ES cell clones that had stably integrated the transgene, an hprt 
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FIGURE 1. Genomic organization of the 
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hFceRla gene and its 5’ regulatory regions. 
Exons are represented by open boxes. 
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minigene was co-electroporated with the DNA fragment. Hypo- 
xanthine aminopterin thymidine-resistant ES cell clones were 
screened for the presence of the hFceRIa gene by Southern blot 
analysis using a human cDNA probe. Examination of 12 clones 
identified 9 that contained at least one copy of the transgene. Be- 
cause the ES cell line into which the transgene was introduced 
already carried a targeted null mutation in one of its endogenous 
FceRIa alleles, the genotype of those cells that had integrated the 
transgene was hFceRIa +, mFceRIa +/-. Two of the ES cell 
lines carrying the transgene were introduced into 3.5-day-old em- 
bryos to produce chimeric mice. 
Expression of hFceRla on mouse mast cells 
Expression of the hFceRIa transgene was first verified by FACS 
analysis of BMMC from female  chimeras  (data not shown). Re- 
sults using chimeras were later verified by FACS analysis of mast 
cells from the offspring of chimeras (Fig. 2 A ) .  BMMCs  from mice 
that were genotyped as hFceR1a +, mFceR1 -I- were expanded 
in culture in the presence of IL-3.  Surface expression of hFceRIa 
was detected by incubating the expanded mast cells with biotiny- 
lated hIgE followed by streptavidin-phycoerythrin. FACS analysis 
revealed high levels of surface expression of hFceRIa in the trans- 
genic mice, but not in control littermates. The specificity of this 
binding was confirmed by the fact that it could be inhibited by 
preincubation of mast cells with the 15-1 Ab, which is specific for 
hFceRIa. 
To estimate the level of expression of the humanized receptor 
relative to that of the endogenous gene,  BMMCs  from mice car- 
rying the transgene and one copy of the endogenous gene were 
stained with biotinylated hIgE or with mouse  IgE after blocking 
the binding to the human receptor with 15-1 Ab. The staining 
intensities of the two different IgE preparations had been calibrated 
previously using Chinese hamster ovary cells transfected with the 
hFceRI a-, D-, and y-chains to ensure that signals with the two 
reagents were comparable and, thus, that differences in staining 
intensity would reflect differences in expression of the two recep- 
tors. In mice carrying the transgene, the humanized receptor was 
found to be expressed on  BMMCs  at levels approximately two- to 
fivefold higher than those normally observed for the endogenous 
receptor in nontransgenic controls. 
In F c ~ R l a  +/- mice carrying the transgene, the level of the 
endogenous mouse receptor at the cell surface was lower than that 
in FceRIa +/- controls that lacked the transgene. This was true 
for  mice derived from both of the original ES cell lines  carrying 
the transgene. We hypothesize that this decrease is caused by com- 
petition of the endogenous a-chain with the human a-chain for 
limited numbers of p- and y-chains. 
To determine whether the 5’ sequences included in the trans- 
gene were sufficient to impart an expression pattern similar to that 
of the endogenous a-chain, we examined RNA isolated from  var- 
ious tissues for message derived from the transgene. No expression 
of the transgene was seen in RNA prepared from kidney, liver, 
testes, spleen, or thymus (data not shown). In addition, Western 
blot analysis using Abs specific for the hFceRI a-chain was con- 
ducted on digitonin-solubilized protein preparations from trans- 
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FIGURE 2. Surface expression of the hFceRla on BMMCs from hu- 
man LY transgenic mice and comparison to endogenous levels of re- 
ceptor. A, BMMCs were  prepared from mice  homozygous for the mu- 
tant mouse allele and  carrying the transgene. Cells  were  labeled  with 
biotinylated hlgE and streptavidin-phycoerythrin. Transgenic mouse 
(dashed line), wild-type  mouse  (solid line), and transgenic mouse 
treated with 15-1 Ab before staining with hlgE (dotted line) are indi- 
cated. 6 and C, BMMCs were prepared from each of the two trans- 
genic lines.  Mice  were  also  heterozygous  for  the  targeted endogenous 
FceRla gene. Cells were labeled  with  biotinylated hlgE and streptavi- 
din-phycoerythrin (dashed line), with biotinylated mouse IgE strepta- 
vidin-phycoerythrin  after  blocking the humanized  receptor with 15-1 
Ab (dotted line), or with streptavidin alone (solid line). 
genic mice. While this approach revealed no expression of the 
humanized receptor in thymocytes or splenocytes, it provided clear 
evidence  for expression of the receptor in BMMCs (Fig. 3A).  
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FIGURE 3. Expression and structure of the humanized FceRl at the 
surface  and in the cytoplasm of BMMC from transgenic mice. Digito- 
nin-solubilized  protein  extracts from  BMMC, thymocytes, and spleno- 
cytes were immunoprecipitated with the 15-1 mAb, and  immunopre- 
cipitated  material was loaded onto an 8% acrylamide gel under 
nonreducing conditions. Western  analysis was carried out with poly- 
clonal antiserum (997) directed against the hFcerla chain. A and 6, 
BMMC from wild-type and transgenic mice were loaded with 15-1 
monoclonal anti-hFccRla Ab, washed, and lysed with 1% digitonin, 
then sequentially  immunoprecipitated  with  protein C beads (surface) 
and beads loaded  with 15-1 Ab (intracellular). Samples were run on a 
14% gel and  transferred to a PVDF membrane. The  upper  part of the 
membrane was  probed  with  an  anti-rat  FceRlp,  and the lower  part was 
probed  with  an anti-mouse FceRly. The molecular mass  is indicated in 
kilodaltons. 
To determine whether the hFceRIa protein in our transgenic 
mice had formed a complex with the mFceRI p- and y-chains, 
mast cells were incubated with the 15-1 Ab. After washing to 
remove unbound Ab, cells  were lysed, and surface-expressed Ab- 
receptor complexes were precipitated with protein G-Sepharose 
beads. The precipitated proteins were analyzed by PAGE followed 
by Western blot analysis with Ab specific for the mFceR1 p- and 
y-chains (Fig. 3). This analysis showed that the human a-chain 
had indeed associated with the mouse p- and y-chains. The pres- 
ence of similar complexes in the cytoplasm of mast cells was dem- 
onstrated by precipitation of additional receptors with 15-1 bound 
to protein G beads from the cell lysate after the initial treatment. 
Activation of mast  cells  through the humanized receptor 
Previous studies have elucidated the chain of events by which mast 
cells  are activated by interaction of IgE with the FceRI receptor. 
After IgE has bound to the a-chain of the receptor, binding of Ag 
to IgE leads to receptor aggregation. This aggregation is followed 
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FIGURE 4. Functionality of the humanized FceRl on 6°C from 
transgenic  mice.  Calcium flux upon  triggering of the humanized and 
murine FceRI from transgenic ( A )  and  wild-type (6) mice. BMMC were 
loaded with fura-2 and sequentially loaded and triggered with hlgE 
and NIP-BSA, respectively,  and  then with  mlgE and DNP-HSA, respec- 
tively.  Cells were lysed  with 1% Triton X-1 00 and Ca2+ chelated with 
EDTA. 
by activation of tyrosine kinases and subsequent phosphorylation 
of the FceRI receptor subunits. One indicator of subsequent mast 
cell degranulation is the release of serotonin. To determine 
whether this  cascade of events could be triggered through the hu- 
manized FceRI receptor on mast cells from transgenic mice, we 
examined increased intracellular calcium and serotonin release as 
indexes of mast cell activation. These experiments were performed 
on BMMC from chimeric animals, in which tissues were com- 
posed of a mixture of blastocyst- and  ES cell-derived cells. In such 
chimeras, cells derived from the blastocyst are mFceRIa +I+, 
while those derived from the injected ES cells are mFceRRIa +/- 
hFceRIa +. Thus, it is expected that, regardless of the function- 
ality of  the humanized FceRI receptor, IgE-mediated responses in 
mast cells derived from these animals should be evoked by binding 
of murine IgE to the mFceRI. 
To test the ability of the humanized FceRI to trigger an intra- 
cellular calcium influx, mast cells grown from chimeras and wild- 
type animals were expanded in culture in the presence of IL-3 and 
then loaded with hIgE specific for NIP. As expected, this treatment 
by itself did not result in a detectable rise in intracellular Ca2+. 
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FIGURE 5.  Serotonin release induced upon triggering of the human- 
ized and murine FceRl from transgenic and wild-type mice. Cells were 
loaded overnight with  [3Hlserotonin. Triggering of the  mast cells was 
performed as indicated in the figure. 
However, addition of NIP-BSA to the hIgE-loaded mast cells re- 
sulted in an increase in free cytoplasmic Ca2' in the mast cells 
derived from the chimeras, but not in those from the wild-type 
animals (Fig. 4). This  same experiment was continued by the  ad- 
dition of mouse IgE specific to  DNP followed by DNP-HSA. As 
expected, this treatment resulted in an increase in free cytoplasmic 
Ca*+ in BMMC  from both wild-type and chimeric animals. 
To assess the ability of the humanized FceRI receptor to trigger 
serotonin release, mast cells from chimeric mice and wild-type 
controls were  expanded  in the presence of IL-3 and loaded with 
radioactive serotonin. Incubation of the cells with the  hIgE specific 
for NIP followed by activation  with the Ag  resulted  in the release of 
serotonin from the  mast cells in a dose-dependent manner (Fig. 5). 
We also sought to compare the level of mast cell activation 
achievable through humanized FceRI with that achievable through 
mFceR1. As mouse IgE can bind to the human receptor, it was 
necessary to block humanized FceRI by the addition of an excess 
of polyclonal hIgE before incubating cells with a monoclonal 
mouse IgE specific for DNP. Subsequent addition of DNP-HSA 
resulted in the release of serotonin from the mast cells. Mast cell 
activation through the human receptor was achieved at far lower 
levels of Ag for several reasons. First, the high level of chimerism 
in these animals, as determined by coat  color, suggested that cells 
carrying the human receptor were likely to greatly outnumber 
those derived from the host blastocyst. In addition, as discussed 
above, the presence of the human receptor significantly reduced 
the level of the mouse receptor relative to that normally seen in 
BMMCs  (Fig. 2, B and C ) .  Finally, differences in valance between 
the NIP  and DNP Ags could contribute to differences in the con- 
centrations of these molecules required for triggering the mast 
cells. 
Restoration of anaphylaxis 
Allergy-like reactions are some of the most important biologic 
responses mediated through the FceRI receptor. To determine 
whether the humanized FceRI receptor expressed in our transgenic 
mice could trigger such reactions, we examined passive systemic 
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FIGURE 6. IgE-mediated systemic anaphylaxis in mice expressing a 
humanized FceRl receptor. A, Changes in rectal  temperatures of 
hFccRla + mFceRla -/- (n = 6), FccRla +/+ (n = 4), and Fc~Rla 
-/- (n = 5) mice during IgE-induced systemic anaphylaxis. Differ- 
ences in temperature taken just before the injection of Ag (1 mg of 
DNP,,-,,-HSA) and 30 min thereafter  were recorded for each animal. 
One group of wild-type animals received only Ag, all other animals 
had received 20 pg of murine anti-DNP IgE 24 h before  the initiation 
of  the experiment. Error  bars  represent the SEM. B, Changes in vascular 
permeability in the  hFceRla + mFccRla -/- (n = 4), FccRla +/+ (n = 
7), and FceRIa -/- (n = 5) mice during IgE-induced systemic ana- 
phylaxis. A 7-mm ear biopsy was  taken from all animals 30 min after 
the injection of 1 mg of DNP,-,-HSA in 0.5% Evans blue dye. All 
animals, with the exception of the wild-type group indicated, had re- 
ceived 20 p g  of anti-DNP IgE 24 h before the initiation of the  exper- 
iment. Error  bars  represent  the SEM. 
anaphylaxis  in  mice with three different genotypes: mFceRIa 
-I-, hFceRIa + mFceRIa -/-, and mFceRIcu +/+. In wild- 
type mice, passive systemic anaphylaxis is typically characterized 
by a number of physiologic changes, including increased vascular 
permeability, generalized fluid extravasation, and profound shock, 
exhibited by a drop  in blood pressure and body temperature (27). 
To elicit the anaphylactic response, mice were injected i.v. with 
a monoclonal IgE  Ab specific for DNP. Twenty-four hours later, 
the DNP Ag was administered. To allow quantitation of  fluid ex- 
travasation, Evans blue dye was administered with the Ag. This 
dye binds to serum proteins and remains largely confined to the 
circulatory system before the change in permeability of the vessels 
following Ag challenge. Extravasation of the dye during the ana- 
phylactic response allows the intensity of the response to be visu- 
alized and quantitated. Control mFceRIa +/+ animals received 
only the Ag and Evans blue dye. 
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The anaphylactic responses in the three groups of animals were 
quantitated in two ways. First, the rectal temperatures of the ani- 
mals were monitored during the responses (Fig. 6 A ) ,  and second, 
the increase in vascular permeability was monitored by measuring 
Evans blue dye in ear tissue (Fig. 6 B ) .  As expected, a significant 
drop in temperature was seen in the wild-type mice relative to that 
in controls treated with DNP only ( p  = 0.003). This drop was 
virtually eliminated in mice homozygous for the null FceRIa al- 
lele, which did not differ significantly in their responses from con- 
trol animals ( p  = 0.48). However, the temperature drop observed 
in hFceRIa + mFccRIa -/- mice was significant ( p  = 0.00004) 
and did not differ significantly from that observed in wild-type 
controls ( p  = 0.93). Although changes in vascular permeability 
observed in FceRIa -/- mice did not differ significantly from 
those in controls ( p  = 0.66), mice expressing hFceRIa did display 
a significant increase in vascular permeability ( p  = 0.05). The 
change in vascular permeability observed in mice expressing 
hFceRIa was not significantly different from that in wild-type mice 
( p  = 0.49). 
Discussion 
Mice expressing the humanized IgE FceRI receptor will provide an 
important tool for investigating a number of aspects of the biology 
of the FceRI receptor. In addition to allowing investigation of the 
molecular mechanisms underlying the tissue-specific distribution 
of the FceRI receptor, they should provide a powerful means of 
assessing the effectiveness of therapeutic agents designed to inter- 
vene in IgE-mediated allergic reactions. 
To generate mice expressing a humanized FceRI receptor, we 
used an approach that combined gene targeting through homolo- 
gous recombination with transgene expression. The production of 
FceRIa-deficient  mice by targeted inactivation of the FceRIa gene 
has been described previously (14). To obtain expression of a hu- 
manized FceRI receptor in these mice, we first transfected a trans- 
gene that encoded the human a-chain into an ES cell line in which 
one of the  endogenous FceRIa alleles had been previously inac- 
tivated by gene targeting. For this purpose we used the  same  cell 
line that had originally been used to produce the FceIRa-deficient 
mice. By introducing the transgene into the mouse germ line via 
ES cells, we were able to examine  the expression pattern of the 
transgene in female chimeras, thus avoiding the large amount of 
breeding that would have been required if  we  had introduced the 
transgene by injection into the pronucleus of single cell mouse 
embryos. The testing of these chimeras allowed us to quickly de- 
termine that the cDNA constructs in which the a gene was driven 
by the HTLV promoter would not yield animals that expressed the 
protein on mast cells.  The relatively small size of the  a-chain  gene 
made it possible to use a genomic fragment containing the entire 
gene, which did yield appropriate expression of the a-chain on the 
surface of mast cells. In addition, the lack of detectable expression 
in other cell types, such as neutrophils, splenocytes, and thymo- 
cytes, supported the contention that the transgene was able to di- 
rect expression of the human a-chain in a tissue-specific manner. 
The human a-chain has been shown to differ from that of the 
mouse in that i t  can be expressed at the cell surface in Langerhans 
cells and also in that its expression in monocytes does not require 
expression of the P-chain. Future examination of the transgenic 
mice for expression of the humanized FceRI receptor on Langer- 
hans cells and monocytes should provide more information about 
the molecular mechanisms underlying differences in expression 
pattern between mice and humans. If the expression pattern of the 
humanized receptor mirrors that in humans, the comparison of 
inflammatory responses in wild-type mice with those in animals 
expressing the humanized receptor should give an indication of the 
importance of Langerhans cells and monocytes in hIgE-mediated 
responses. 
For mice expressing the humanized FceRI receptor to provide a 
useful model of responses mediated through the hFceRI receptor, 
it was first necessary to show not only that the humanized receptor 
was expressed at the surface and could bind IgE, but also that it  
could carry out the signal transduction required for normal IgE- 
mediated responses. We first demonstrated coimmunoprecipitation 
of the endogenous FceRIP and y-chains with an anti-hFceRIa Ab, 
thus establishing that the human a-chain was able to form receptor 
complexes with the murine 0- and y-chains. We then showed that 
the humanized receptor is as efficient as the endogenous murine 
receptor in initiating signal transduction, as assessed by the release 
of intracellular Ca2+ and subsequent release of serotonin. These 
data also provide evidence that the human a-chain is able to in- 
teract with the murine P- and y-chains, as both chains are required 
for efficient signa1 transduction. 
We have also shown that the humanized FceRI receptor is able 
to mediate an  in vivo anaphylactic response, since the presence of 
the human transgene restored this response to our FceRIa-deficient 
mice. This result indicates that the transgene is expressed in those 
cells that normally mediate anaphylaxis. In addition, the ability of 
mice carrying the humanized receptor to undergo anaphylaxis 
upon binding of hIgE indicates that these animals will provide an 
important test system for the design of compounds that interfere 
with the binding of IgE to the hFceRI receptor. 
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